Logo     Print Page  Close Window


SEC Filings


10-Q
FIBROCELL SCIENCE, INC. filed this Form 10-Q on 08/09/2018
Entire Document
 

Fibrocell Science, Inc.
Condensed Consolidated Statement of Stockholders’ Equity (Deficit)
(unaudited)
($ in thousands, except share data) 

 
Series A Convertible
Preferred Stock
 
Common Stock
 
Additional paid-in capital
 
Accumulated deficit
 
Total Equity
 
Shares
 
Amount
 
Shares
 
Amount
 
 
 
Balance, December 31, 2017
8,000

 
$

 
5,189,755

 
5

 
$
187,805

 
$
(178,803
)
 
$
9,007

Conversion of pre-funded warrants

 

 
483,221

 
1

 
23

 

 
24

Stock-based compensation expense

 

 

 

 
260

 

 
260

May 2018 Registered Direct Offering, net of offering costs of $627

 

 
2,038,224

 
2

 
5,371

 

 
5,373

Exercise of warrants

 

 
129,702

 

 
499

 

 
499

Net loss

 

 

 

 

 
(5,795
)
 
(5,795
)
Balance, June 30, 2018
8,000

 
$

 
7,840,902

 
$
8

 
$
193,958

 
$
(184,598
)
 
$
9,368

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.



7